Skip to the beginning of the images gallery

Recombinant AMPK gamma 1 Antibody - Primary antibody, specific to AMPK gamma 1, Rabbit IgG

ExactAb™
Recombinant
Validated
0.5 mg/mL

Features and benefits

Short Overview:
Recombinant; Rabbit anti Human AMPK gamma 1 Antibody; WB, ICC, IF; Unconjugated
Species reactivity(Reacts with): Human
Isotype: Rabbit IgG

Application:

IF/ICC
WB

Item Number

Ab088680

Grouped product items
SKU	Size	Availability	Price
Ab088680-10μl	10μl	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$66.90
Ab088680-50μl	50μl	In stock	$189.90
Ab088680-100μl	100μl	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$289.90
Ab088680-1ml	1ml	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,599.90

Recombinant; Rabbit anti Human AMPK gamma 1 Antibody; WB, ICC, IF; Unconjugated

View related series

Accession#:P54619 AMPK gamma 1 Gene ID:5571 PRKAG1

Basic Description

Product Name	Recombinant AMPK gamma 1 Antibody - Primary antibody, specific to AMPK gamma 1, Rabbit IgG
Synonyms	5' AMP activated protein kinasegamma 1 subunit antibody; 5' AMP activated protein kinase subunit gamma 1 antibody; 5''-AMP-activated protein kinase subunit gamma-1 antibody; AAKG1_HUMAN antibody; AMP activated protein kinase noncatalytic gamma 1 subunit a
Specifications & Purity	ExactAb™, Validated, Recombinant, 0.5 mg/mL
Host species	Rabbit
Specificity	AMPK gamma 1
Immunogen	A synthetic peptide derived from human AMPK gamma 1 (AA 1-19)
Positive Control	WB: HeLa, A549, HL-60, U20S lysates. ICC/IF: HeLa cells.
Conjugation	Unconjugated
Grade	ExactAb™, Recombinant, Validated
Product Description	Rabbit anti Human AMPK gamma 1 Antibody, Recombinant, could be used for WB, IF, ICC and so on. Application: WB: 1/500-1/1000 ICC/IF: 1/50-1/200 Protein Function: AMP/ATP-binding subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Gamma non-catalytic subunit mediates binding to AMP, ADP and ATP, leading to activate or inhibit AMPK: AMP-binding results in allosteric activation of alpha catalytic subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and preventing dephosphorylation of catalytic subunits. ADP also stimulates phosphorylation, without stimulating already phosphorylated catalytic subunit. ATP promotes dephosphorylation of catalytic subunit, rendering the AMPK enzyme inactive.

Product Properties

Isotype	Rabbit IgG
SDS-PAGE	150 kDa
Purification Method	Antigen affinity purification
Form	Liquid
Concentration	0.5 mg/mL
Storage Temp	Store at -20°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant AMPK gamma 1 Antibody (Ab088680) - Western Blot
All lanes: Recombinant AMPK gamma 1 Antibody (Ab088680) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 38 kDa
Observed band size: 36 kDa
Exposure time: 24.7 s

Recombinant AMPK gamma 1 Antibody (Ab088680) - IF/ICC
Immunocytochemistry analysis of AMPK gamma 1 (green) in HeLa using Recombinant AMPK gamma 1 Antibody (Ab088680), and cells were counterstained with DAPI (blue).

Associated Targets

PRKAG1 Tchem 5'-AMP-activated protein kinase subunit gamma-1 0 Activities

Discover Target: PRKAG1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application

Application	Dilution info
WB	1/500-1/1000
ICC/IF	1/50-1/200

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot Number	Certificate Type	Date	Item
ZJ23F1202192	Certificate of Analysis	Dec 28, 2023	Ab088680
ZJ23F1202191	Certificate of Analysis	Dec 28, 2023	Ab088680

FAQs and Articles

FAQ

In-cell ELISA protocol

Categories: Protocols

Tags:

Monoclonal antibodies In-cell ELISA Cytoblot Protein quantification HRP-Conjugated Secondary Antibodies Polyclonal Antibodies

References

1. Towler MC, Hardie DG. (2007) AMP-activated protein kinase in metabolic control and insulin signaling.. Circ Res, 100 (3): (328-41). [PMID:17307971]
2. Soth M, Hermann JC, Yee C, Alam M, Barnett JW, Berry P, Browner MF, Frank K, Frauchiger S, Harris S et al.. (2013) 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.. J Med Chem, 56 (1): (345-56). [PMID:23214979]
3. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099]
4. Machrouhi F, Ouhamou N, Laderoute K, Calaoagan J, Bukhtiyarova M, Ehrlich PJ, Klon AE. (2010) The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity.. Bioorg Med Chem Lett, 20 (22): (6394-9). [PMID:20932747]
5. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.. Nat Chem Biol, 4 (11): (691-9). [PMID:18849971]
6. Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O et al.. (2013) Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.. J Med Chem, 56 (20): (8032-48). [PMID:24044867]
7. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. (2009) Inhibitor hijacking of Akt activation.. Nat Chem Biol, 5 (7): (484-93). [PMID:19465931]
8. Lainchbury M, Matthews TP, McHardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de Haven Brandon AK, Box G et al.. (2012) Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.. J Med Chem, 55 (22): (10229-40). [PMID:23082860]
9. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
10. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G et al.. (2017) Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.. Bioorg Med Chem, 25 (4): (1320-1328). [PMID:28038940]
11. Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, Patel BR, Heath RB, Walker PA, Hallen S et al.. (2013) Structural basis of AMPK regulation by small molecule activators.. Nat Commun, 4 (3): (3017). [PMID:24352254]
12. Reich SH, Sprengeler PA, Chiang GG, Appleman JR, Chen J, Clarine J, Eam B, Ernst JT, Han Q, Goel VK et al.. (2018) Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.. J Med Chem, 61 (8): (3516-3540). [PMID:29526098]
13. Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KN. (2017) Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.. Bioorg Med Chem, 25 (9): (2609-2616). [PMID:28351607]
14. Erki Enkvist, Darja Lavogina, Gerda Raidaru, Angela Vaasa, Indrek Viil, Marje Lust, Kaido Viht, Asko Uri,. (2006-11-28) Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases.. Journal of medicinal chemistry, 49 ((24)): ( 7150-7159 ). [PMID:17125267]
15. Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S.. (2006) Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.. J Med Chem, 49 (7): (2210-2221). [PMID:16570917]
16. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G.. (2006) Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.. J Med Chem, 49 (15): (4455-4458). [PMID:16854050]
17. Hugon B, Anizon F, Bailly C, Golsteyn RM, Pierré A, Léonce S, Hickman J, Pfeiffer B, Prudhomme M.. (2007) Synthesis and biological activities of isogranulatimide analogues.. Bioorg Med Chem, 15 (17): (5965-5980). [PMID:17582773]
18. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424]
19. Guh JH, Chang WL, Yang J, Lee SL, Wei S, Wang D, Kulp SK, Chen CS.. (2010) Development of novel adenosine monophosphate-activated protein kinase activators.. J Med Chem, 53 (6): (2552-2561). [PMID:20170185]
20. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD.. (2009) Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.. Bioorg Med Chem Lett, 19 (21): (6122-6126). [PMID:19783434]
21. Oh S, Kim SJ, Hwang JH, Lee HY, Ryu MJ, Park J, Kim SJ, Jo YS, Kim YK, Lee CH, Kweon KR, Shong M, Park SB.. (2010) Antidiabetic and antiobesity effects of Ampkinone (6f), a novel small molecule activator of AMP-activated protein kinase.. J Med Chem, 53 (20): (7405-7413). [PMID:20873794]
22. Qin N, Li CB, Jin MN, Shi LH, Duan HQ, Niu WY.. (2011) Synthesis and biological activity of novel tiliroside derivants.. Eur J Med Chem, 46 (10): (5189-5195). [PMID:21856048]
23. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM.. (2012) Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.. Bioorg Med Chem Lett, 22 (5): (2015-2019). [PMID:22335895]
24. Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Jordan AD, Masucci JA, Jones WJ, Abad MC, Gibbs AC, Petrounia I.. (2011) Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.. ACS Med Chem Lett, 2 (7): (538-543). [PMID:24900346]
25. Andreani A, Granaiola M, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Farruggia G, Stefanelli C, Masotti L, Nguyen TL, Hamel E, Shoemaker RH.. (2012) Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action.. J Med Chem, 55 (5): (2078-2088). [PMID:22283430]
26. Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Gibbs AC, Connelly MA.. (2012) Pyrimidinopyrimidine inhibitors of ketohexokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket.. Bioorg Med Chem Lett, 22 (16): (5326-5329). [PMID:22795331]
27. Malmström J, Viklund J, Slivo C, Costa A, Maudet M, Sandelin C, Hiller G, Olsson LL, Aagaard A, Geschwindner S, Xue Y, Vasänge M.. (2012) Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors.. Bioorg Med Chem Lett, 22 (18): (5919-5923). [PMID:22889803]
28. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.. (2013) Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.. J Med Chem, 56 (9): (3456-3466). [PMID:23550937]
29. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S.. (2013) Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.. Bioorg Med Chem Lett, 23 (6): (1588-1591). [PMID:23414803]
30. Yu LF, Li YY, Su MB, Zhang M, Zhang W, Zhang LN, Pang T, Zhang RT, Liu B, Li JY, Li J, Nan FJ.. (2013) Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators.. ACS Med Chem Lett, 4 (5): (475-480). [PMID:24900695]
31. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709]
32. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M.. (2013) Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.. Bioorg Med Chem Lett, 23 (9): (2743-2749). [PMID:23522834]
33. Yuan T, Nahar P, Sharma M, Liu K, Slitt A, Aisa HA, Seeram NP.. (2014) Indazole-type alkaloids from Nigella sativa seeds exhibit antihyperglycemic effects via AMPK activation in vitro.. J Nat Prod, 77 (10): (2316-2320). [PMID:25299458]
34. Xie F, Zhu H, Zhang H, Lang Q, Tang L, Huang Q, Yu L.. (2015) In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor.. Eur J Med Chem, 89 (310-319). [PMID:25462247]
35. Rana S, Blowers EC, Natarajan A.. (2015) Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.. J Med Chem, 58 (1): (2-29). [PMID:25122135]
36. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT.. (2015) Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.. Eur J Med Chem, 100 (151-161). [PMID:26081023]
37. Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar A, Bharate SB.. (2015) Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.. Bioorg Med Chem Lett, 25 (15): (2948-2952). [PMID:26048785]
38. Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Notarangelo A, Breschi MC, Macchia M, Martini C, Rapposelli S.. (2015) Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.. Eur J Med Chem, 105 (274-288). [PMID:26498573]
39. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T.. (2015) Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.. Bioorg Med Chem Lett, 25 (24): (5687-5693). [PMID:26547690]
40. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J.. (2016) 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.. J Med Chem, 59 (4): (1388-1409). [PMID:26741168]
41. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810]
42. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA.. (2016) A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.. Bioorg Med Chem Lett, 26 (15): (3457-3463). [PMID:27363938]
43. Klaeger S, Heinzlmeir S and Wilhelm M et al. (2017) The target landscape of clinical kinase drugs.. Science, 358 (6367): [PMID:29191878]
44. Mook RA, Ren XR, Wang J, Piao H, Barak LS, Kim Lyerly H, Chen W.. (2017) Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.. Bioorg Med Chem, 25 (6): (1804-1816). [PMID:28233680]
45. Hoemann M, Wilson N, Argiriadi M, Banach D, Burchat A, Calderwood D, Clapham B, Cox P, Duignan DB, Konopacki D, Somal G, Vasudevan A.. (2016) Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.. Bioorg Med Chem Lett, 26 (22): (5562-5567). [PMID:27789138]
46. Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, Hu L.. (2017) Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).. Eur J Med Chem, 127 (72-86). [PMID:28038328]
47. Lan P, Romero FA, Wodka D, Kassick AJ, Dang Q, Gibson T, Cashion D, Zhou G, Chen Y, Zhang X, Zhang A, Li Y, Trujillo ME, Shao Q, Wu M, Xu S, He H, MacKenna D, Staunton J, Chapman KT, Weber A, Sebhat IK, Makara GM.. (2017) Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase.. J Med Chem, 60 (21): (9040-9052). [PMID:29035567]
48. Ouyang L, Zhang L, Liu J, Fu L, Yao D, Zhao Y, Zhang S, Wang G, He G, Liu B.. (2017) Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.. J Med Chem, 60 (24): (9990-10012). [PMID:29172540]
49. Gouda AM, Abdelazeem AH, Omar HA, Abdalla AN, Abourehab MAS, Ali HI.. (2017) Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action.. Bioorg Med Chem, 25 (20): (5637-5651). [PMID:28916158]
50. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y.. (2017) Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.. Eur J Med Chem, 135 (12-23). [PMID:28426996]
51. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS79182026: A potent orally active hepcidin production inhibitor.. Bioorg Med Chem Lett, 27 (16): (3716-3722). [PMID:28705644]
52. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471]
53. Zhou S, Duan Y, Wang J, Zhang J, Sun H, Jiang H, Gu Z, Tong J, Li J, Li J, Liu H.. (2017) Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes.. Eur J Med Chem, 140 (448-464). [PMID:28987606]
54. Wang T, Jiang H, Cao S, Chen Q, Cui M, Wang Z, Li D, Zhou J, Wang T, Qiu F, Kang N.. (2017) Baicalin and its metabolites suppresses gluconeogenesis through activation of AMPK or AKT in insulin resistant HepG-2 cells.. Eur J Med Chem, 141 (92-100). [PMID:29028535]
55. Jose J, Tavares CDJ, Ebelt ND, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KN.. (2017) Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.. ACS Med Chem Lett, 8 (10): (1072-1076). [PMID:29057053]
56. Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA.. (2017) Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 27 (8): (1867-1873). [PMID:28279528]
57. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C.. (2018) Effects of rigidity on the selectivity of protein kinase inhibitors.. Eur J Med Chem, 146 (519-528). [PMID:29407977]
58. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946]
59. Wang J, Mook RA, Ren XR, Zhang Q, Jing G, Lu M, Spasojevic I, Lyerly HK, Hsu D, Chen W.. (2018) Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.. Bioorg Med Chem, 26 (20): (5435-5442). [PMID:30274939]
60. Zhang W, Sviripa VM, Kril LM, Yu T, Xie Y, Hubbard WB, Sullivan PG, Chen X, Zhan CG, Yang-Hartwich Y, Evers BM, Spear BT, Gedaly R, Watt DS, Liu C.. (2019) An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors.. J Med Chem, 62 (24): (11348-11358). [PMID:31774672]
61. Osborne J, Birchall K, Tsagris DJ, Lewis SJ, Smiljanic-Hurley E, Taylor DL, Levy A, Alessi DR, McIver EG.. (2019) Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1.. Bioorg Med Chem Lett, 29 (4): (668-673). [PMID:30554956]
62. Abdelaziz AM, Basnet SKC, Islam S, Li M, Tadesse S, Albrecht H, Gerber C, Yu M, Wang S.. (2019) Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.. Bioorg Med Chem Lett, 29 (18): (2650-2654). [PMID:31362920]
63. Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A, Őrfi L.. (2018) Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.. J Med Chem, 61 (14): (6277-6292). [PMID:29928803]
64. Tong L, Song P, Jiang K, Xu L, Jin T, Wang P, Hu X, Fang S, Gao A, Zhou Y, Liu T, Li J, Hu Y.. (2019) Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.. Eur J Med Chem, 173 (44-62). [PMID:30986571]
65. Yang W, Li Y, Ai Y, Obianom ON, Guo D, Yang H, Sakamuru S, Xia M, Shu Y, Xue F.. (2019) Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation.. J Med Chem, 62 (24): (11151-11164). [PMID:31769984]
66. Chen Y, Li Q, Li Q, Xing S, Liu Y, Liu Y, Chen Y, Liu W, Feng F, Sun H.. (2020) p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.. J Med Chem, 63 (18): (10135-10157). [PMID:32324396]
67. Yuan X,Wu H,Bu H,Zheng P,Zhou J,Zhang H. (2019) Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.. Bioorg Med Chem, 27 (7.0): (1211-1225). [PMID:30824167]
68. Runfola M,Sestito S,Bellusci L,La Pietra V,D'Amore VM,Kowalik MA,Chiellini G,Gul S,Perra A,Columbano A,Marinelli L,Novellino E,Rapposelli S. (2020) Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.. Eur J Med Chem, 188 (112006-112006). [PMID:31931337]
69. Gao, G G and 7 more authors.. (1996) Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-activated protein kinase.. The Journal of biological chemistry, (12): [PMID:8621499]
70. Scott, John W JW and 7 more authors.. (2004) CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations.. The Journal of clinical investigation, [PMID:14722619]
71. Scherer, Steven E SE and 216 more authors.. (2006) The finished DNA sequence of human chromosome 12.. Nature, (16): [PMID:16541075]
72. Baba, Masaya M and 16 more authors.. (2006) Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.. Proceedings of the National Academy of Sciences of the United States of America, (17): [PMID:17028174]
73. Scott, John W JW, Ross, Fiona A FA, Liu, J K David JK and Hardie, D Grahame DG.. (2007) Regulation of AMP-activated protein kinase by a pseudosubstrate sequence on the gamma subunit.. The EMBO journal, (7): [PMID:17255938]
74. Hasumi, Hisashi H and 8 more authors.. (2008) Identification and characterization of a novel folliculin-interacting protein FNIP2.. Gene, (31): [PMID:18403135]
75. Daub, Henrik H and 9 more authors.. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.. Molecular cell, (8): [PMID:18691976]
76. Hao, Jijun and 8 more authors.. (2010) In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.. ACS chemical biology, (19): [PMID:20020776]
77. Löffler, Antje S AS and 9 more authors.. (2011) Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop.. Autophagy, [PMID:21460634]
78. Din, Farhat V N FV and 7 more authors.. (2012) Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.. Gastroenterology, [PMID:22406476]
79. Hawley, Simon A and 13 more authors.. (2012) The ancient drug salicylate directly activates AMP-activated protein kinase.. Science (New York, N.Y.), (18): [PMID:22517326]
80. Steinberg, Gregory R; Dandapani, Madhumita and Hardie, D Grahame.. (2013) AMPK: mediating the metabolic effects of salicylate-based drugs?. Trends in endocrinology and metabolism: TEM, [PMID:23871515]
81. Bian, Yangyang Y and 9 more authors.. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.. Journal of proteomics, (16): [PMID:24275569]
82. Li, Xiaodan X and 10 more authors.. (2015) Structural basis of AMPK regulation by adenine nucleotides and glycogen.. Cell research, [PMID:25412657]
83. Marín-Aguilar, Fabiola; Pavillard, Luis E; Giampieri, Francesca; Bullón, Pedro and Cordero, Mario D.. (2017) Adenosine Monophosphate (AMP)-Activated Protein Kinase: A New Target for Nutraceutical Compounds.. International journal of molecular sciences, (29): [PMID:28146060]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.